Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 28, 2024 (filed on Mar 28, 2024)Insider Name:Fitzgerald Kevin JosephOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 28, 2024 (filed on Mar 28, 2024)Insider Name:Fitzgerald Kevin JosephOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 28, 2024 (filed on Mar 28, 2024)Insider Name:Fitzgerald Kevin JosephOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 28, 2024 (filed on Mar 28, 2024)Insider Name:Fitzgerald Kevin JosephOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 28, 2024 (filed on Mar 28, 2024)Insider Name:Fitzgerald Kevin JosephOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 28, 2024 (filed on Mar 28, 2024)Insider Name:Fitzgerald Kevin JosephOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 28, 2024 (filed on Mar 28, 2024)Insider Name:Fitzgerald Kevin JosephOwnership Type:Direct OwnershipSecurities:Performance Stock Option 2017 (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 28, 2024 (filed on Mar 28, 2024)Insider Name:Fitzgerald Kevin JosephOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 28, 2024 (filed on Mar 28, 2024)Insider Name:Fitzgerald Kevin JosephOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 28, 2024 (filed on Mar 28, 2024)Insider Name:Fitzgerald Kevin JosephOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
Filings by filing date
-
Mar 28, 2024 (filed on Mar 28, 2024)Insider Name:Fitzgerald Kevin JosephOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 28, 2024 (filed on Mar 28, 2024)Insider Name:Fitzgerald Kevin JosephOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 28, 2024 (filed on Mar 28, 2024)Insider Name:Fitzgerald Kevin JosephOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 28, 2024 (filed on Mar 28, 2024)Insider Name:Fitzgerald Kevin JosephOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 28, 2024 (filed on Mar 28, 2024)Insider Name:Fitzgerald Kevin JosephOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 28, 2024 (filed on Mar 28, 2024)Insider Name:Fitzgerald Kevin JosephOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 28, 2024 (filed on Mar 28, 2024)Insider Name:Fitzgerald Kevin JosephOwnership Type:Direct OwnershipSecurities:Performance Stock Option 2017 (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 28, 2024 (filed on Mar 28, 2024)Insider Name:Fitzgerald Kevin JosephOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 28, 2024 (filed on Mar 28, 2024)Insider Name:Fitzgerald Kevin JosephOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Mar 28, 2024 (filed on Mar 28, 2024)Insider Name:Fitzgerald Kevin JosephOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 675 W Kendall St CAMBRIDGE MA 02142-1168 |
Tel: | N/A |
Website: | https://www.alnylam.com |
IR: | See website |
Key People | ||
Yvonne L. Greenstreet Chief Executive Officer, Director | Jeffrey V. Poulton Chief Financial Officer, Executive Vice President | Pushkal P. Garg Chief Medical Officer, Executive Vice President - Development and Medical Affairs |
Michael W. Bonney Chief Compliance Officer, Director | Tolga Tanguler Chief Commercial Officer | Akshay K. Vaishnaw Part Time Chief Innovation Officer |
Business Overview |
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company's lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity. |
Financial Overview |
For the fiscal year ended 31 December 2023, Alnylam Pharmaceuticals, Inc. revenues increased 76% to $1.83B. Net loss decreased 61% to $440.2M. Revenues reflect AMVUTTRA segment increase from $93.8M to $557.8M, Other segment increase from $10.3M to $399.6M, Europe segment increase of 27% to $399.3M, United States segment increase of 12% to $689M. Lower net loss reflects Loss on the extinguishment of debt decrease from $76.6M (expense) to $0K. |
Employees: | 2,100 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $16,862M as of Dec 31, 2023 |
Annual revenue (TTM): | $1,828M as of Dec 31, 2023 |
EBITDA (TTM): | -$228.12M as of Dec 31, 2023 |
Net annual income (TTM): | -$440.24M as of Dec 31, 2023 |
Free cash flow (TTM): | $41.95M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 125,933,946 as of Mar 22, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |